Literature DB >> 17900616

Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics.

Shantanu Sharma1, Peng Gong, Brenda Temple, Debadeep Bhattacharyya, Nikolay V Dokholyan, Stephen G Chaney.   

Abstract

Mismatch repair proteins, DNA damage-recognition proteins and translesion DNA polymerases discriminate between Pt-GG adducts containing cis-diammine ligands (formed by cisplatin (CP) and carboplatin) and trans-RR-diaminocyclohexane ligands (formed by oxaliplatin (OX)) and this discrimination is thought to be important in determining differences in the efficacy, toxicity and mutagenicity of these platinum anticancer agents. We have postulated that these proteins recognize differences in conformation and/or conformational dynamics of the DNA containing the adducts. We have previously determined the NMR solution structure of OX-DNA, CP-DNA and undamaged duplex DNA in the 5'-d(CCTCAGGCCTCC)-3' sequence context and have shown the existence of several conformational differences in the vicinity of the Pt-GG adduct. Here we have used molecular dynamics simulations to explore differences in the conformational dynamics between OX-DNA, CP-DNA and undamaged DNA in the same sequence context. Twenty-five 10 ns unrestrained fully solvated molecular dynamics simulations were performed starting from two different DNA conformations using AMBER v8.0. All 25 simulations reached equilibrium within 4 ns, were independent of the starting structure and were in close agreement with previous crystal and NMR structures. Our data show that the cis-diammine (CP) ligand preferentially forms hydrogen bonds on the 5' side of the Pt-GG adduct, while the trans-RR-diaminocyclohexane (OX) ligand preferentially forms hydrogen bonds on the 3' side of the adduct. In addition, our data show that these differences in hydrogen bond formation are strongly correlated with differences in conformational dynamics, specifically the fraction of time spent in different DNA conformations in the vicinity of the adduct, for CP- and OX-DNA adducts. We postulate that differential recognition of CP- and OX-GG adducts by mismatch repair proteins, DNA damage-recognition proteins and DNA polymerases may be due, in part, to differences in the fraction of time that the adducts spend in a conformation favorable for protein binding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900616      PMCID: PMC2129172          DOI: 10.1016/j.jmb.2007.07.079

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  44 in total

1.  Mismatch extension ability of yeast and human DNA polymerase eta.

Authors:  M T Washington; R E Johnson; S Prakash; L Prakash
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

2.  The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch.

Authors:  M H Lamers; A Perrakis; J H Enzlin; H H Winterwerp; N de Wind; T K Sixma
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

3.  Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA.

Authors:  L G Marzilli; J S Saad; Z Kuklenyik; K A Keating; Y Xu
Journal:  J Am Chem Soc       Date:  2001-03-28       Impact factor: 15.419

4.  HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.

Authors:  S M Cohen; Y Mikata; Q He; S J Lippard
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

5.  The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.

Authors:  A Vaisman; S G Chaney
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

6.  Mechanisms of accurate translesion synthesis by human DNA polymerase eta.

Authors:  C Masutani; R Kusumoto; S Iwai; F Hanaoka
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

7.  Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA.

Authors:  G Obmolova; C Ban; P Hsieh; W Yang
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

8.  Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

Authors:  A Vaisman; C Masutani; F Hanaoka; S G Chaney
Journal:  Biochemistry       Date:  2000-04-25       Impact factor: 3.162

9.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.

Authors:  A Vaisman; M Varchenko; A Umar; T A Kunkel; J I Risinger; J C Barrett; T C Hamilton; S G Chaney
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

10.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

Authors:  J M Woynarowski; W G Chapman; C Napier; M C Herzig; P Juniewicz
Journal:  Mol Pharmacol       Date:  1998-11       Impact factor: 4.436

View more
  19 in total

1.  Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.

Authors:  C L King; S Ramachandran; S G Chaney; L Collins; J A Swenberg; K E DeKrafft; W Lin; L Cicurel; M Barbier
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

2.  Empirical force field for cisplatin based on quantum dynamics data: case study of new parameterization scheme for coordination compounds.

Authors:  S Yesylevskyy; Bruno Cardey; S Kraszewski; Sarah Foley; Mironel Enescu; Antônio M da Silva; Hélio F Dos Santos; Christophe Ramseyer
Journal:  J Mol Model       Date:  2015-09-19       Impact factor: 1.810

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

4.  Atomic level rendering of DNA-drug encounter.

Authors:  Maria F Lucas; Israel Cabeza de Vaca; Ryoji Takahashi; Jaime Rubio-Martínez; Víctor Guallar
Journal:  Biophys J       Date:  2014-01-21       Impact factor: 4.033

5.  Non-specificity and synergy at the binding site of the carboplatin-induced DNA adduct via molecular dynamics simulations of the MutSα-DNA recognition complex.

Authors:  Lacramioara Negureanu; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2013-06-25

6.  Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein.

Authors:  Robert M Elder; Arthi Jayaraman
Journal:  Biophys J       Date:  2012-05-15       Impact factor: 4.033

Review 7.  Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease.

Authors:  Cynthia T McMurray
Journal:  DNA Repair (Amst)       Date:  2008-05-09

Review 8.  Inhibition of transcription by platinum antitumor compounds.

Authors:  Ryan C Todd; Stephen J Lippard
Journal:  Metallomics       Date:  2009       Impact factor: 4.526

9.  Differences in conformational dynamics of [Pt3(HPTAB)]6+-DNA adducts with various cross-linking modes.

Authors:  Yanyan Zhu; Yan Wang; Guangju Chen
Journal:  Nucleic Acids Res       Date:  2009-08-04       Impact factor: 16.971

Review 10.  Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response.

Authors:  Jeremy Z R Han; Jordan F Hastings; Monica Phimmachanh; Dirk Fey; Walter Kolch; David R Croucher
Journal:  J Pers Med       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.